用于测定接受棘白菌素联合治疗患者伏立康唑血清水平的生物测定法。
Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins.
作者信息
Siopi Maria, Neroutsos Efthymios, Zisaki Kalliopi, Gamaletsou Maria, Pirounaki Maria, Tsirigotis Panagiotis, Sipsas Nikolaos, Dokoumetzidis Aristides, Goussetis Evgenios, Zerva Loukia, Valsami Georgia, Meletiadis Joseph
机构信息
Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
Antimicrob Agents Chemother. 2015 Oct 26;60(1):632-6. doi: 10.1128/AAC.01688-15. Print 2016 Jan.
Voriconazole levels were determined with high-performance liquid chromatography (HPLC) and a microbiological agar diffusion assay using a Candida parapsilosis isolate in 103 serum samples from an HPLC-tested external quality control program (n = 39), 21 patients receiving voriconazole monotherapy (n = 39), and 7 patients receiving combination therapy (n = 25). The results of the bioassay were correlated with the results obtained from the external quality control program samples and with the HPLC results in sera from patients on voriconazole monotherapy and on combination therapy with an echinocandin (Spearman's rank correlation coefficient [rs], > 0.93; mean ± standard error of the mean [SEM] % difference, <12% ± 3.8%).
伏立康唑血药浓度采用高效液相色谱法（HPLC）以及使用近平滑念珠菌分离株的微生物琼脂扩散法进行测定，样本来自一个经过HPLC检测的外部质量控制项目的103份血清样本（n = 39）、21例接受伏立康唑单药治疗的患者（n = 39）以及7例接受联合治疗的患者（n = 25）。生物测定结果与外部质量控制项目样本的结果以及伏立康唑单药治疗患者和棘白菌素联合治疗患者血清中的HPLC结果相关（斯皮尔曼等级相关系数[rs]，> 0.93；平均±平均标准误[SEM]差异百分比，<12% ± 3.8%）。
Zotero 插件